A Phase I/II Trial of AK112 in Advanced Solid Tumor
Latest Information Update: 12 Mar 2025
At a glance
- Drugs Ivonescimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Akeso Biopharma
Most Recent Events
- 30 Oct 2024 Status changed from active, no longer recruiting to completed.
- 08 Oct 2022 Status changed from not yet recruiting to active, no longer recruiting.
- 28 Oct 2020 New trial record